1-7 of 7
Emmanuel Normant, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4001.
https://doi.org/10.1182/blood-2019-126951
Published: 2019
Journal Articles

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Pamela M Holland, PhD, Emmanuel Normant, PhD, Ammar Adam, DVM, Caroline M Armet, BS, Rachel W O'Connor, BS, Andrew C Lake, PhD, Jonathan A Hill, PhD, Detlev M Biniskiewicz, PhD, Scott C Chappel, PhD, Vito J Palombella, PhD, Alison M Paterson, PhD
Journal: Blood
Blood (2016) 128 (22): 1843.
https://doi.org/10.1182/blood.V128.22.1843.1843
Published: 2016
Journal Articles

Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor

Mary T Scott, PhD, Koorosh Korfi, PhD, Paolo Gallipoli, PhD, Peter Saffrey, PhD, Heather Jorgensen, PhD, Michelle Cruz, Ashley Hamilton, PhD, Amy Sinclair, Andrew Crossan, PhD, Emmanuel Normant, PhD, Vidya Balasubramanian, Tessa L. Holyoake, PhD, David Vetrie, PhD
Journal: Blood
Blood (2013) 122 (21): 2710.
https://doi.org/10.1182/blood.V122.21.2710.2710
Published: 2013
Journal Articles

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Kerstin M Kampa, MD, Tanja Grandl, Sandra Mueller, Emmanuel Normant, PhD, Michael Walter, PhD, Wolfgang Schuetz, PhD, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD
Journal: Blood
Blood (2009) 114 (22): 2753.
https://doi.org/10.1182/blood.V114.22.2753.2753
Published: 2009
Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD
Journal: Blood
Blood (2006) 108 (11): 3579.
https://doi.org/10.1182/blood.V108.11.3579.3579
Published: 2006
Journal Articles

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Warren Fiskus, PhD, Purva Bali, MS, Michael Pranpat, MS, Maria Balasis, BS, Sandhya Kumaraswamy, PhD, Sandhya Boyapalle, PhD, Kathy Rocha, BS, Jeffery Tong, MD, Victoria Richon, PhD, Emmanuel Normant, PhD, Kapil Bhalla, MD
Journal: Blood
Blood (2005) 106 (11): 4461.
https://doi.org/10.1182/blood.V106.11.4461.4461
Published: 2005
Journal Articles

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Sundar Jagannath, MD, David Siegel, MD, Paul Richardson, MD, Amitabha Mazumder, MD, Jens Sydor, PhD, Jill Goddard, John Walker, Jon Patterson, Emmanuel Normant, PhD, Jeffrey Tong, PhD, Vito Palombella, PhD, Ken Anderson, MD, Julian Adams, PhD, David Grayzel, MD
Journal: Blood
Blood (2005) 106 (11): 2560.
https://doi.org/10.1182/blood.V106.11.2560.2560
Published: 2005